News
Novo Nordisk keeps nose ahead of Lilly with oral GLP-1 filing
Shares in Eli Lilly shot up last Thursday after the US pharma major announced positive top-line Phase III results from ACHIEVE-1, comparing orforglipron to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.
Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk. The Dallas Wings introduced their newest ...
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has been struggling during the past year. Its financial results - ...
Novo Nordisk now has an Ozempic pill. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday ...
Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...
Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...
In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback